Analysis of CLDN18.2 expression in gastric and GEJ cancers

Manish A. Shah, Director of the Gastrointestinal Oncology Program at Weill Cornell Medical College, shared on X:

“Happy to report our analysis of CLDN18.2 expression globally! Important for those who will receive CLDN18.2 targeted Rx for gastric and gastroesophageal junction cancers!

Zolbetuximab is already approved in Japan! Hopefully we’ll have access soon! ”

Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

Source: Manish A. Shah/X